Title :

Long-term fatigue in survivors of non-hodgkin lymphoma: the lymphoma study association simonal cross-sectional study

Author(s) :

Mounier, Nicolas [Auteur]
Anthony, Sabine [Auteur]
Busson, Raphael [Auteur]
Thieblemont, Catherine [Auteur]
Ribrag, Vincent [Auteur]
Tilly, Herve [Auteur]
Haioun, Corinne [Auteur]
Casasnovas, Rene-Olivier [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Feugier, Pierre [Auteur]
Delarue, Richard [Auteur]
Ysebaert, Loic [Auteur]
Sebban, Catherine [Auteur]
Broussais-Guillaumot, Florence [Auteur]
Damaj, Gandhi [Auteur]
Nerich, Virginie [Auteur]
Jais, Jean-Philippe [Auteur]
Laborde, Lilian [Auteur]
Salles, Gilles [Auteur]
Henry-Amar, Michel [Auteur]

Journal title :

Cancer

Abbreviated title :

Cancer

Publication date :

2019-03-22

ISSN :

1097-0142

English keyword(s) :

risk factors
cross-sectional study
long-term fatigue
long-term survivors
non-Hodgkin lymphomas

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: Long-term survivors of non-Hodgkin lymphoma (NHL) must cope with treatment complications and late toxicities that affect their health-related quality of life. Little is known about the risk-to-benefit ratio of ...
Show more >BACKGROUND: Long-term survivors of non-Hodgkin lymphoma (NHL) must cope with treatment complications and late toxicities that affect their health-related quality of life. Little is known about the risk-to-benefit ratio of new agents like rituximab. The impact of treatment regimens and health disorders on long-term fatigue levels was investigated in a cross-sectional study. METHODS: Two self-administered questionnaires, the 20-item Multidimensional Fatigue Inventory (MFI-20) and a Life Situation Questionnaire, were mailed in 2015 to NHL survivors enrolled onto 12 successive clinical studies (1993-2010) conducted by the Lymphoma Study Association. Private addresses were obtained for 3317 survivors, of whom 1671 (50%) returned the questionnaires. Severe fatigue was defined as MFI-20 scores ≥60 on dimension scales scored from 0 to 100. Linear regression models were used to assess factors that were linked to increased fatigue levels. RESULTS: The study population included 906 men and 765 women, and the median age was 64 years (age range, 24-95 years). Overall, 811 survivors had received cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like chemotherapy, 518 had received high-dose CHOP, and 342 had undergone upfront autologous stem cell transplantation; 829 survivors also had received rituximab. In total, 1100 survivors (66%) reported 1 or more late health disorders. Severe fatigue was reported by 602 survivors (37%). Increased fatigue levels were associated (P < .001) with increased age, obesity, and the presence of health disorders, but not with initial treatment or rituximab. CONCLUSIONS: The survey confirms that high proportions long-term NHL survivors have severe fatigue. The results suggest that initial treatment and the receipt of rituximab have no influence on the development of long-term fatigue.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Research team(s) :

Modélisation biopharmaceutique et pharmacocinétique

Submission date :

2019-12-16T14:06:44Z